Olivia Wilkins, Allison M. Keeler et Terence R. Flotte, « CAR T-Cell Therapy: Progress and Prospects », Human Gene Therapy Methods, vol. 28, no 2, , p. 61–66 (ISSN1946-6536, DOI10.1089/hgtb.2016.153, lire en ligne, consulté le ).
Michael C. Milone, Jonathan D. Fish, Carmine Carpenito et Richard G. Carroll, « Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo », Molecular Therapy: the Journal of the American Society of Gene Therapy, vol. 17, no 8, , p. 1453–1464 (ISSN1525-0016, PMID19384291, PMCIDPMC2805264, DOI10.1038/mt.2009.83, lire en ligne, consulté le ).
David L. Porter, Bruce L. Levine, Michael Kalos et Adam Bagg, « Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia », The New England Journal of Medicine, vol. 365, no 8, , p. 725–733 (ISSN0028-4793, PMID21830940, PMCIDPMC3387277, DOI10.1056/NEJMoa1103849, lire en ligne, consulté le ).
Renier Brentjens, Marco L Davila, Isabelle Riviere et Jae Park, « CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia », Science translational medicine, vol. 5, no 177, , p. 177ra38 (ISSN1946-6234, PMID23515080, PMCIDPMC3742551, DOI10.1126/scitranslmed.3005930, lire en ligne, consulté le ).
James N. Kochenderfer, Wyndham H. Wilson, John E. Janik et Mark E. Dudley, « Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 », Blood, vol. 116, no 20, , p. 4099–4102 (ISSN0006-4971, PMID20668228, PMCIDPMC2993617, DOI10.1182/blood-2010-04-281931, lire en ligne, consulté le ).
S. A. Rosenberg, B. S. Packard, P. M. Aebersold et D. Solomon, « Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report », The New England Journal of Medicine, vol. 319, no 25, , p. 1676–1680 (ISSN0028-4793, PMID3264384, DOI10.1056/NEJM198812223192527, lire en ligne, consulté le ).
Stephanie L. Goff, Mark E. Dudley, Deborah E. Citrin et Robert P. Somerville, « Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma », Journal of Clinical Oncology, vol. 34, no 20, , p. 2389–2397 (ISSN0732-183X, PMID27217459, PMCIDPMC4981979, DOI10.1200/JCO.2016.66.7220, lire en ligne, consulté le ).
David L. Porter, Wei-Ting Hwang, Noelle V. Frey et Simon F. Lacey, « Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia », Science translational medicine, vol. 7, no 303, , p. 303ra139 (ISSN1946-6234, PMID26333935, PMCIDPMC5909068, DOI10.1126/scitranslmed.aac5415, lire en ligne, consulté le ).
Barbara Savoldo, Carlos Almeida Ramos, Enli Liu et Martha P. Mims, « CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients », The Journal of Clinical Investigation, vol. 121, no 5, , p. 1822–1826 (ISSN0021-9738, PMID21540550, PMCIDPMC3083795, DOI10.1172/JCI46110, lire en ligne, consulté le ).
(en) Richard A Morgan, James C Yang, Mio Kitano et Mark E Dudley, « Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2 », Molecular Therapy, vol. 18, no 4, , p. 843–851 (PMID20179677, PMCIDPMC2862534, DOI10.1038/mt.2010.24, lire en ligne, consulté le )
(en) Kris M. Mahadeo, Sajad J. Khazal, Hisham Abdel-Azim et Julie C. Fitzgerald, « Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy », Nature Reviews Clinical Oncology, vol. 16, no 1, , p. 45–63 (ISSN1759-4782, PMID30082906, PMCIDPMC7096894, DOI10.1038/s41571-018-0075-2, lire en ligne, consulté le )
Ping-Pin Zheng, Johan M. Kros et Jin Li, « Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts », Drug Discovery Today, vol. 23, no 6, , p. 1175–1182 (ISSN1359-6446, DOI10.1016/j.drudis.2018.02.012, lire en ligne, consulté le )
Shruti Gupta, Harish Seethapathy, Ian A. Strohbehn et Matthew J. Frigault, « Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma », American Journal of Kidney Diseases, vol. 76, no 1, , p. 63–71 (ISSN0272-6386, PMID31973908, PMCIDPMC7311244, DOI10.1053/j.ajkd.2019.10.011, lire en ligne, consulté le )
Daniel W. Lee, Bianca D. Santomasso, Frederick L. Locke et Armin Ghobadi, « ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells », Biology of Blood and Marrow Transplantation, vol. 25, no 4, , p. 625–638 (ISSN1083-8791, DOI10.1016/j.bbmt.2018.12.758, lire en ligne, consulté le )
Runxia Gu, Fang Liu, Dehui Zou et Yingxi Xu, « Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia », Journal of Hematology & Oncology, vol. 13, no 1, , p. 122 (ISSN1756-8722, PMID32894185, PMCIDPMC7487702, DOI10.1186/s13045-020-00953-8, lire en ligne, consulté le )
(en) Waseem Qasim, Hong Zhan, Sujith Samarasinghe et Stuart Adams, « Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells », Science Translational Medicine, vol. 9, no 374, , eaaj2013 (ISSN1946-6234 et 1946-6242, PMID28123068, DOI10.1126/scitranslmed.aaj2013, lire en ligne, consulté le ).
Markus Chmielewski, Caroline Kopecky, Andreas A. Hombach et Hinrich Abken, « IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression », Cancer Research, vol. 71, no 17, , p. 5697–5706 (ISSN1538-7445, PMID21742772, DOI10.1158/0008-5472.CAN-11-0103, lire en ligne, consulté le ).
Gray Kueberuwa, Milena Kalaitsidou, Eleanor Cheadle et Robert Edward Hawkins, « CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity », Molecular Therapy Oncolytics, vol. 8, , p. 41–51 (ISSN2372-7705, PMID29367945, PMCIDPMC5772011, DOI10.1016/j.omto.2017.12.003, lire en ligne, consulté le ).
(en) Thiago Carvalho, « mRNA vaccines boost BioNTech’s CAR T cell therapy », Nature Medicine, vol. 28, no 10, , p. 1968–1969 (DOI10.1038/d41591-022-00091-3, lire en ligne, consulté le )
Ping-Pin Zheng, Johan M. Kros et Jin Li, « Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts », Drug Discovery Today, vol. 23, no 6, , p. 1175–1182 (ISSN1359-6446, DOI10.1016/j.drudis.2018.02.012, lire en ligne, consulté le )
Shruti Gupta, Harish Seethapathy, Ian A. Strohbehn et Matthew J. Frigault, « Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma », American Journal of Kidney Diseases, vol. 76, no 1, , p. 63–71 (ISSN0272-6386, PMID31973908, PMCIDPMC7311244, DOI10.1053/j.ajkd.2019.10.011, lire en ligne, consulté le )
Daniel W. Lee, Bianca D. Santomasso, Frederick L. Locke et Armin Ghobadi, « ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells », Biology of Blood and Marrow Transplantation, vol. 25, no 4, , p. 625–638 (ISSN1083-8791, DOI10.1016/j.bbmt.2018.12.758, lire en ligne, consulté le )
Runxia Gu, Fang Liu, Dehui Zou et Yingxi Xu, « Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia », Journal of Hematology & Oncology, vol. 13, no 1, , p. 122 (ISSN1756-8722, PMID32894185, PMCIDPMC7487702, DOI10.1186/s13045-020-00953-8, lire en ligne, consulté le )
(en) Richard A Morgan, James C Yang, Mio Kitano et Mark E Dudley, « Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2 », Molecular Therapy, vol. 18, no 4, , p. 843–851 (PMID20179677, PMCIDPMC2862534, DOI10.1038/mt.2010.24, lire en ligne, consulté le )
Olivia Wilkins, Allison M. Keeler et Terence R. Flotte, « CAR T-Cell Therapy: Progress and Prospects », Human Gene Therapy Methods, vol. 28, no 2, , p. 61–66 (ISSN1946-6536, DOI10.1089/hgtb.2016.153, lire en ligne, consulté le ).
Y. Kuwana, Y. Asakura, N. Utsunomiya et M. Nakanishi, « Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions », Biochemical and Biophysical Research Communications, vol. 149, no 3, , p. 960–968 (ISSN0006-291X, PMID3122749, lire en ligne, consulté le ).
G Gross, T Waks et Z Eshhar, « Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. », Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no 24, , p. 10024–10028 (ISSN0027-8424, PMID2513569, lire en ligne, consulté le ).
R. H. Schwartz, D. L. Mueller, M. K. Jenkins et H. Quill, « T-cell clonal anergy », Cold Spring Harbor Symposia on Quantitative Biology, vol. 54 Pt 2, , p. 605–610 (ISSN0091-7451, PMID2534840, lire en ligne, consulté le ).
Michael C. Milone, Jonathan D. Fish, Carmine Carpenito et Richard G. Carroll, « Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo », Molecular Therapy: the Journal of the American Society of Gene Therapy, vol. 17, no 8, , p. 1453–1464 (ISSN1525-0016, PMID19384291, PMCIDPMC2805264, DOI10.1038/mt.2009.83, lire en ligne, consulté le ).
David L. Porter, Bruce L. Levine, Michael Kalos et Adam Bagg, « Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia », The New England Journal of Medicine, vol. 365, no 8, , p. 725–733 (ISSN0028-4793, PMID21830940, PMCIDPMC3387277, DOI10.1056/NEJMoa1103849, lire en ligne, consulté le ).
Renier Brentjens, Marco L Davila, Isabelle Riviere et Jae Park, « CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia », Science translational medicine, vol. 5, no 177, , p. 177ra38 (ISSN1946-6234, PMID23515080, PMCIDPMC3742551, DOI10.1126/scitranslmed.3005930, lire en ligne, consulté le ).
James N. Kochenderfer, Wyndham H. Wilson, John E. Janik et Mark E. Dudley, « Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 », Blood, vol. 116, no 20, , p. 4099–4102 (ISSN0006-4971, PMID20668228, PMCIDPMC2993617, DOI10.1182/blood-2010-04-281931, lire en ligne, consulté le ).
S. A. Rosenberg, B. S. Packard, P. M. Aebersold et D. Solomon, « Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report », The New England Journal of Medicine, vol. 319, no 25, , p. 1676–1680 (ISSN0028-4793, PMID3264384, DOI10.1056/NEJM198812223192527, lire en ligne, consulté le ).
Stephanie L. Goff, Mark E. Dudley, Deborah E. Citrin et Robert P. Somerville, « Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma », Journal of Clinical Oncology, vol. 34, no 20, , p. 2389–2397 (ISSN0732-183X, PMID27217459, PMCIDPMC4981979, DOI10.1200/JCO.2016.66.7220, lire en ligne, consulté le ).
David L. Porter, Wei-Ting Hwang, Noelle V. Frey et Simon F. Lacey, « Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia », Science translational medicine, vol. 7, no 303, , p. 303ra139 (ISSN1946-6234, PMID26333935, PMCIDPMC5909068, DOI10.1126/scitranslmed.aac5415, lire en ligne, consulté le ).
Barbara Savoldo, Carlos Almeida Ramos, Enli Liu et Martha P. Mims, « CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients », The Journal of Clinical Investigation, vol. 121, no 5, , p. 1822–1826 (ISSN0021-9738, PMID21540550, PMCIDPMC3083795, DOI10.1172/JCI46110, lire en ligne, consulté le ).
(en) Kris M. Mahadeo, Sajad J. Khazal, Hisham Abdel-Azim et Julie C. Fitzgerald, « Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy », Nature Reviews Clinical Oncology, vol. 16, no 1, , p. 45–63 (ISSN1759-4782, PMID30082906, PMCIDPMC7096894, DOI10.1038/s41571-018-0075-2, lire en ligne, consulté le )
Ping-Pin Zheng, Johan M. Kros et Jin Li, « Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts », Drug Discovery Today, vol. 23, no 6, , p. 1175–1182 (ISSN1359-6446, DOI10.1016/j.drudis.2018.02.012, lire en ligne, consulté le )
Shruti Gupta, Harish Seethapathy, Ian A. Strohbehn et Matthew J. Frigault, « Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma », American Journal of Kidney Diseases, vol. 76, no 1, , p. 63–71 (ISSN0272-6386, PMID31973908, PMCIDPMC7311244, DOI10.1053/j.ajkd.2019.10.011, lire en ligne, consulté le )
Daniel W. Lee, Bianca D. Santomasso, Frederick L. Locke et Armin Ghobadi, « ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells », Biology of Blood and Marrow Transplantation, vol. 25, no 4, , p. 625–638 (ISSN1083-8791, DOI10.1016/j.bbmt.2018.12.758, lire en ligne, consulté le )
Runxia Gu, Fang Liu, Dehui Zou et Yingxi Xu, « Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia », Journal of Hematology & Oncology, vol. 13, no 1, , p. 122 (ISSN1756-8722, PMID32894185, PMCIDPMC7487702, DOI10.1186/s13045-020-00953-8, lire en ligne, consulté le )
(en) Waseem Qasim, Hong Zhan, Sujith Samarasinghe et Stuart Adams, « Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells », Science Translational Medicine, vol. 9, no 374, , eaaj2013 (ISSN1946-6234 et 1946-6242, PMID28123068, DOI10.1126/scitranslmed.aaj2013, lire en ligne, consulté le ).
Jon G. Quatromoni et Evgeniy Eruslanov, « Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer », American Journal of Translational Research, vol. 4, no 4, , p. 376–389 (ISSN1943-8141, PMID23145206, PMCIDPMC3493031, lire en ligne, consulté le ).
Pratima Sinha, Virginia K. Clements, Stephanie K. Bunt et Steven M. Albelda, « Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response », Journal of Immunology (Baltimore, Md.: 1950), vol. 179, no 2, , p. 977–983 (ISSN0022-1767, PMID17617589, lire en ligne, consulté le ).
Markus Chmielewski, Caroline Kopecky, Andreas A. Hombach et Hinrich Abken, « IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression », Cancer Research, vol. 71, no 17, , p. 5697–5706 (ISSN1538-7445, PMID21742772, DOI10.1158/0008-5472.CAN-11-0103, lire en ligne, consulté le ).
Gray Kueberuwa, Milena Kalaitsidou, Eleanor Cheadle et Robert Edward Hawkins, « CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity », Molecular Therapy Oncolytics, vol. 8, , p. 41–51 (ISSN2372-7705, PMID29367945, PMCIDPMC5772011, DOI10.1016/j.omto.2017.12.003, lire en ligne, consulté le ).
Olivia Wilkins, Allison M. Keeler et Terence R. Flotte, « CAR T-Cell Therapy: Progress and Prospects », Human Gene Therapy Methods, vol. 28, no 2, , p. 61–66 (ISSN1946-6536, DOI10.1089/hgtb.2016.153, lire en ligne, consulté le ).
(en) Kris M. Mahadeo, Sajad J. Khazal, Hisham Abdel-Azim et Julie C. Fitzgerald, « Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy », Nature Reviews Clinical Oncology, vol. 16, no 1, , p. 45–63 (ISSN1759-4782, PMID30082906, PMCIDPMC7096894, DOI10.1038/s41571-018-0075-2, lire en ligne, consulté le )
(en) Thiago Carvalho, « mRNA vaccines boost BioNTech’s CAR T cell therapy », Nature Medicine, vol. 28, no 10, , p. 1968–1969 (DOI10.1038/d41591-022-00091-3, lire en ligne, consulté le )
Y. Kuwana, Y. Asakura, N. Utsunomiya et M. Nakanishi, « Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions », Biochemical and Biophysical Research Communications, vol. 149, no 3, , p. 960–968 (ISSN0006-291X, PMID3122749, lire en ligne, consulté le ).
G Gross, T Waks et Z Eshhar, « Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. », Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no 24, , p. 10024–10028 (ISSN0027-8424, PMID2513569, lire en ligne, consulté le ).
R. H. Schwartz, D. L. Mueller, M. K. Jenkins et H. Quill, « T-cell clonal anergy », Cold Spring Harbor Symposia on Quantitative Biology, vol. 54 Pt 2, , p. 605–610 (ISSN0091-7451, PMID2534840, lire en ligne, consulté le ).
Michael C. Milone, Jonathan D. Fish, Carmine Carpenito et Richard G. Carroll, « Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo », Molecular Therapy: the Journal of the American Society of Gene Therapy, vol. 17, no 8, , p. 1453–1464 (ISSN1525-0016, PMID19384291, PMCIDPMC2805264, DOI10.1038/mt.2009.83, lire en ligne, consulté le ).
David L. Porter, Bruce L. Levine, Michael Kalos et Adam Bagg, « Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia », The New England Journal of Medicine, vol. 365, no 8, , p. 725–733 (ISSN0028-4793, PMID21830940, PMCIDPMC3387277, DOI10.1056/NEJMoa1103849, lire en ligne, consulté le ).
Renier Brentjens, Marco L Davila, Isabelle Riviere et Jae Park, « CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia », Science translational medicine, vol. 5, no 177, , p. 177ra38 (ISSN1946-6234, PMID23515080, PMCIDPMC3742551, DOI10.1126/scitranslmed.3005930, lire en ligne, consulté le ).
James N. Kochenderfer, Wyndham H. Wilson, John E. Janik et Mark E. Dudley, « Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 », Blood, vol. 116, no 20, , p. 4099–4102 (ISSN0006-4971, PMID20668228, PMCIDPMC2993617, DOI10.1182/blood-2010-04-281931, lire en ligne, consulté le ).
S. A. Rosenberg, B. S. Packard, P. M. Aebersold et D. Solomon, « Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report », The New England Journal of Medicine, vol. 319, no 25, , p. 1676–1680 (ISSN0028-4793, PMID3264384, DOI10.1056/NEJM198812223192527, lire en ligne, consulté le ).
Stephanie L. Goff, Mark E. Dudley, Deborah E. Citrin et Robert P. Somerville, « Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma », Journal of Clinical Oncology, vol. 34, no 20, , p. 2389–2397 (ISSN0732-183X, PMID27217459, PMCIDPMC4981979, DOI10.1200/JCO.2016.66.7220, lire en ligne, consulté le ).
David L. Porter, Wei-Ting Hwang, Noelle V. Frey et Simon F. Lacey, « Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia », Science translational medicine, vol. 7, no 303, , p. 303ra139 (ISSN1946-6234, PMID26333935, PMCIDPMC5909068, DOI10.1126/scitranslmed.aac5415, lire en ligne, consulté le ).
Barbara Savoldo, Carlos Almeida Ramos, Enli Liu et Martha P. Mims, « CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients », The Journal of Clinical Investigation, vol. 121, no 5, , p. 1822–1826 (ISSN0021-9738, PMID21540550, PMCIDPMC3083795, DOI10.1172/JCI46110, lire en ligne, consulté le ).
(en) Richard A Morgan, James C Yang, Mio Kitano et Mark E Dudley, « Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2 », Molecular Therapy, vol. 18, no 4, , p. 843–851 (PMID20179677, PMCIDPMC2862534, DOI10.1038/mt.2010.24, lire en ligne, consulté le )
(en) Kris M. Mahadeo, Sajad J. Khazal, Hisham Abdel-Azim et Julie C. Fitzgerald, « Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy », Nature Reviews Clinical Oncology, vol. 16, no 1, , p. 45–63 (ISSN1759-4782, PMID30082906, PMCIDPMC7096894, DOI10.1038/s41571-018-0075-2, lire en ligne, consulté le )
Shruti Gupta, Harish Seethapathy, Ian A. Strohbehn et Matthew J. Frigault, « Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma », American Journal of Kidney Diseases, vol. 76, no 1, , p. 63–71 (ISSN0272-6386, PMID31973908, PMCIDPMC7311244, DOI10.1053/j.ajkd.2019.10.011, lire en ligne, consulté le )
Runxia Gu, Fang Liu, Dehui Zou et Yingxi Xu, « Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia », Journal of Hematology & Oncology, vol. 13, no 1, , p. 122 (ISSN1756-8722, PMID32894185, PMCIDPMC7487702, DOI10.1186/s13045-020-00953-8, lire en ligne, consulté le )
(en) Waseem Qasim, Hong Zhan, Sujith Samarasinghe et Stuart Adams, « Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells », Science Translational Medicine, vol. 9, no 374, , eaaj2013 (ISSN1946-6234 et 1946-6242, PMID28123068, DOI10.1126/scitranslmed.aaj2013, lire en ligne, consulté le ).
Jon G. Quatromoni et Evgeniy Eruslanov, « Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer », American Journal of Translational Research, vol. 4, no 4, , p. 376–389 (ISSN1943-8141, PMID23145206, PMCIDPMC3493031, lire en ligne, consulté le ).
Pratima Sinha, Virginia K. Clements, Stephanie K. Bunt et Steven M. Albelda, « Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response », Journal of Immunology (Baltimore, Md.: 1950), vol. 179, no 2, , p. 977–983 (ISSN0022-1767, PMID17617589, lire en ligne, consulté le ).
Markus Chmielewski, Caroline Kopecky, Andreas A. Hombach et Hinrich Abken, « IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression », Cancer Research, vol. 71, no 17, , p. 5697–5706 (ISSN1538-7445, PMID21742772, DOI10.1158/0008-5472.CAN-11-0103, lire en ligne, consulté le ).
Gray Kueberuwa, Milena Kalaitsidou, Eleanor Cheadle et Robert Edward Hawkins, « CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity », Molecular Therapy Oncolytics, vol. 8, , p. 41–51 (ISSN2372-7705, PMID29367945, PMCIDPMC5772011, DOI10.1016/j.omto.2017.12.003, lire en ligne, consulté le ).
(en) Waseem Qasim, Hong Zhan, Sujith Samarasinghe et Stuart Adams, « Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells », Science Translational Medicine, vol. 9, no 374, , eaaj2013 (ISSN1946-6234 et 1946-6242, PMID28123068, DOI10.1126/scitranslmed.aaj2013, lire en ligne, consulté le ).